CAPP2 Paper Released

posted on Friday, 28th October 2011

Not tagged.

We invited just over 1000 people to take two aspirins or two placebo tablets daily for at least 2 years. They were also asked to take two sachets of either resistant indigestible starch powder or cornstarch. After two years they were invited to stay on for a second two year period. We started recruiting in 1999 and reached our total in 2005.  At the end of the intervention stage there was no difference in the number of cancers or precancerous polyps in any go the groups. When the first recruits reached the planned 10 year follow-up stage we did a second analysis. The overall average follow up at this point was an average of five years. We found that the people in the aspirin group had significantly fewer cancers. This was most clear in the ones who had taken aspirin for at least two years.

There were 10 new cancers in the aspirin group compared to 23 in the placebo group.  The statistical analysis showed that the number of colorectal cancers in the treatment group was reduced by 63%. We had also planned to look at the total number of Lynch syndrome cancers, including endometrial, gastric and renal cancers etc.  We found the same effect with 19 cancers in the aspirin group and 38 in the placebo group.

The bottom line is that people with Lynch syndrome should consider taking daily aspirin. The next question is to ask whether we get the same benefit from a lower dose of aspirin. Anyone with Lynch syndrome who wants to help should leave us their contact details and we will keep them informed of our new study which will compare two aspirin daily with groups on one tablet or a "baby" aspirin to see what happens over the next five years.

For more information you can donwload the CAPP2 Press Release.

Share this!

Latest News

Downloads